암 진단 제휴 및 라이선싱 계약(2018-2026년)

The definitive benchmark for cancer diagnostics dealmaking

Cancer diagnostics partnering sits at the intersection of precision medicine and oncology, with deal structures reflecting the integration of diagnostic technologies, data, and therapeutic development strategies.

This report provides a comprehensive and structured analysis of 800+ cancer diagnostic collaboration and licensing deals, delivering a clear and evidence-based view of how partnerships are designed, negotiated, and executed across the market.

Establish a clear view of market standards

The report enables a precise understanding of how cancer diagnostic deals are structured in practice, allowing you to:

• Benchmark comparable transactions with confidence
• Detailed analysis of upfronts, milestones, and royalty structures across relevant deals
• Define realistic market parameters
• Clear insight into how deal terms vary by technology type, application, and partner profile
• Support valuation and structuring decisions with evidence
• Ground internal discussions in real transaction data rather than assumptions
• Understand how leading companies approach dealmaking
• Visibility into partner behaviour and recurring deal structures across a precision medicine-driven and technology-led landscape
• Full visibility into deal structure and execution
• Beyond headline deal data, the report provides access to underlying contract documents, enabling a detailed understanding of how agreements are constructed in practice.

This includes:

• Rights granted and retained
• Development and commercialization responsibilities
• Financial structures and payment triggers
• Key contractual provisions and protections
• This level of transparency is critical to understanding how value, risk, and control are allocated within cancer diagnostic partnerships, particularly where companion diagnostics, data integration, and co-development with therapeutics are key considerations.
• Designed for real-world BD and strategy use

The report is widely used to:

• Structure and benchmark diagnostic and oncology partnerships
• Prepare for negotiations with well-defined market context
• Evaluate technology partners and collaboration opportunities
• Support internal strategy with robust, defensible data
• What's included
• 800+ cancer diagnostic collaboration and licensing deals
• Financial terms, including upfronts, milestones, and royalties where disclosed
• Fully searchable deal directory (by company, technology, and application)
• Direct access to SEC-filed agreements and source documents
• Analysis of deal trends, key transactions, and active dealmakers
• A trusted, evidence-based reference for cancer diagnostics dealmaking
• Combining comprehensive deal coverage with contract-level insight, this report provides a trusted, evidence-based reference for how cancer diagnostic partnerships are structured, negotiated, and valued.

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in cancer diagnostic dealmaking

• 2.1. Introduction
• 2.2. Cancer diagnostic deals over the years
• 2.3. Most active cancer diagnostic dealmakers
• 2.4. Cancer diagnostic deals by deal type
• 2.5. Cancer diagnostic deals by therapy area
• 2.6. Cancer diagnostic deals by industry sector
• 2.7. Deal terms for cancer diagnostic deals
  • 2.7.1 Cancer diagnostic deals headline values
  • 2.7.2 Cancer diagnostic deal upfront payments
  • 2.7.3 Cancer diagnostic deal milestone payments
  • 2.7.4 Cancer diagnostic royalty rates

Chapter 3 - Leading cancer diagnostic deals

• 3.1. Introduction
• 3.2. Top cancer diagnostic deals by value

Chapter 4 - Most active cancer diagnostic dealmakers

• 4.1. Introduction
• 4.2. Most active cancer diagnostic dealmakers
• 4.3. Most active cancer diagnostic deals company profiles

Chapter 5 - Cancer diagnostic contracts dealmaking directory

• 5.1. Introduction
• 5.2. Cancer diagnostic contracts dealmaking directory

Chapter 6 - Cancer diagnostic dealmaking by technology type

• Deal directory
• Deal directory - Cancer diagnostic deals by company A-Z
• Deal directory - Cancer diagnostic deals by deal type
• Deal directory - Cancer diagnostic deals by therapy area
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Cancer diagnostic deals since 2018
• Figure 2: Active cancer diagnostic dealmaking activity since 2018
• Figure 3: Cancer diagnostic deals by deal type since 2018
• Figure 4: Cancer diagnostic deals by therapy area since 2018
• Figure 5: Cancer diagnostic deals by industry sector since 2018
• Figure 6: Cancer diagnostic deals with a headline value
• Figure 7: Cancer diagnostic deals with an upfront value
• Figure 8: Cancer diagnostic deals with a milestone value
• Figure 9: Cancer diagnostic deals with a royalty rate value
• Figure 10: Top cancer diagnostic deals by value since 2018
• Figure 11: Most active cancer diagnostic dealmakers since 2018
• Figure 12: Cancer diagnostic deals by technology type since 2018